vs
PATHWARD FINANCIAL, INC.（CASH）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
PATHWARD FINANCIAL, INC.的季度营收约是Pacira BioSciences, Inc.的1.6倍（$276.3M vs $177.4M），PATHWARD FINANCIAL, INC.净利率更高（26.4% vs 1.6%，领先24.7%），过去两年PATHWARD FINANCIAL, INC.的营收复合增速更高（21.0% vs -0.2%）
Pathward Financial, Inc.是一家总部位于美国的银行及金融服务企业，其前身为Meta金融集团旗下相关业务主体，2022年母公司将“Meta”商标出售给Meta Platforms后，正式启用现有名称。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
CASH vs PCRX — 直观对比
营收规模更大
CASH
是对方的1.6倍
$177.4M
净利率更高
CASH
高出24.7%
1.6%
两年增速更快
CASH
近两年复合增速
-0.2%
损益表 — Q2 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $276.3M | $177.4M |
| 净利润 | $72.9M | $2.9M |
| 毛利率 | — | — |
| 营业利润率 | — | 3.9% |
| 净利率 | 26.4% | 1.6% |
| 营收同比 | — | 5.0% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $3.35 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CASHPCRX
| Q1 26 | $276.3M | $177.4M | ||
| Q4 25 | $173.1M | $196.9M | ||
| Q3 25 | $186.7M | $179.5M | ||
| Q2 25 | $195.8M | $181.1M | ||
| Q1 25 | $274.8M | $168.9M | ||
| Q4 24 | $182.6M | $187.3M | ||
| Q3 24 | $179.5M | $168.6M | ||
| Q2 24 | $188.6M | $178.0M |
净利润CASHPCRX
| Q1 26 | $72.9M | $2.9M | ||
| Q4 25 | $35.2M | — | ||
| Q3 25 | $38.8M | $5.4M | ||
| Q2 25 | $42.1M | $-4.8M | ||
| Q1 25 | $75.0M | $4.8M | ||
| Q4 24 | $30.0M | — | ||
| Q3 24 | $33.5M | $-143.5M | ||
| Q2 24 | $44.9M | $18.9M |
毛利率CASHPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
营业利润率CASHPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | 24.6% | 1.2% | ||
| Q3 25 | 25.9% | 3.5% | ||
| Q2 25 | 24.1% | 4.7% | ||
| Q1 25 | 33.2% | 1.2% | ||
| Q4 24 | 19.8% | 13.2% | ||
| Q3 24 | 20.9% | -82.8% | ||
| Q2 24 | 27.1% | 15.9% |
净利率CASHPCRX
| Q1 26 | 26.4% | 1.6% | ||
| Q4 25 | 20.3% | — | ||
| Q3 25 | 20.8% | 3.0% | ||
| Q2 25 | 21.5% | -2.7% | ||
| Q1 25 | 27.3% | 2.8% | ||
| Q4 24 | 16.4% | — | ||
| Q3 24 | 18.7% | -85.1% | ||
| Q2 24 | 23.8% | 10.6% |
每股收益（稀释后）CASHPCRX
| Q1 26 | $3.35 | $0.07 | ||
| Q4 25 | $1.57 | $0.05 | ||
| Q3 25 | $1.69 | $0.12 | ||
| Q2 25 | $1.81 | $-0.11 | ||
| Q1 25 | $3.14 | $0.10 | ||
| Q4 24 | $1.23 | $0.38 | ||
| Q3 24 | $1.34 | $-3.11 | ||
| Q2 24 | $1.78 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $157.6M | $144.3M |
| 总债务越低越好 | $59.5M | — |
| 股东权益账面价值 | $850.7M | $653.9M |
| 总资产 | $7.1B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资CASHPCRX
| Q1 26 | $157.6M | $144.3M | ||
| Q4 25 | $331.2M | $238.4M | ||
| Q3 25 | $120.6M | $246.3M | ||
| Q2 25 | $258.3M | $445.9M | ||
| Q1 25 | $254.2M | $493.6M | ||
| Q4 24 | $597.4M | $484.6M | ||
| Q3 24 | $158.3M | $453.8M | ||
| Q2 24 | $298.9M | $404.2M |
总债务CASHPCRX
| Q1 26 | $59.5M | — | ||
| Q4 25 | $33.5M | $372.2M | ||
| Q3 25 | $33.5M | $376.7M | ||
| Q2 25 | $33.4M | $580.5M | ||
| Q1 25 | $33.4M | $583.4M | ||
| Q4 24 | $33.4M | $585.3M | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $33.3M | — |
股东权益CASHPCRX
| Q1 26 | $850.7M | $653.9M | ||
| Q4 25 | $854.5M | $693.1M | ||
| Q3 25 | $858.0M | $727.2M | ||
| Q2 25 | $819.0M | $757.8M | ||
| Q1 25 | $814.7M | $798.5M | ||
| Q4 24 | $758.3M | $778.3M | ||
| Q3 24 | $822.5M | $749.6M | ||
| Q2 24 | $748.4M | $879.3M |
总资产CASHPCRX
| Q1 26 | $7.1B | $1.2B | ||
| Q4 25 | $7.6B | $1.3B | ||
| Q3 25 | $7.2B | $1.3B | ||
| Q2 25 | $7.2B | $1.5B | ||
| Q1 25 | $7.0B | $1.6B | ||
| Q4 24 | $7.6B | $1.6B | ||
| Q3 24 | $7.5B | $1.5B | ||
| Q2 24 | $7.5B | $1.6B |
负债/权益比CASHPCRX
| Q1 26 | 0.07× | — | ||
| Q4 25 | 0.04× | 0.54× | ||
| Q3 25 | 0.04× | 0.52× | ||
| Q2 25 | 0.04× | 0.77× | ||
| Q1 25 | 0.04× | 0.73× | ||
| Q4 24 | 0.04× | 0.75× | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CASH
| Noninterest Income | $151.2M | 55% |
| Net Interest Income | $125.1M | 45% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
